• No results found

The prevalence of acute Chlamydia pneumoniae infection in patients with acute exacerbation of the chronic obstructive pulmonary

N/A
N/A
Protected

Academic year: 2021

Share "The prevalence of acute Chlamydia pneumoniae infection in patients with acute exacerbation of the chronic obstructive pulmonary"

Copied!
8
0
0

Loading.... (view fulltext now)

Full text

(1)

* لﻮﺌﺴﻣهﺪﻨﺴﻳﻮﻧ : ،دﺮﻛﺮﻬﺷ ،ﻲﻧﻮﻔﻋ يﺎﻫ يرﺎﻤﻴﺑ هوﺮﮔ ،دﺮﻛﺮﻬﺷ ﻲﻜﺷﺰﭘ مﻮﻠﻋ هﺎﮕﺸﻧاد . ﻦﻔﻠﺗ : 09133815531 ، rastabi669@gmail.com E- mail:

ﺪﻳﺪﺷ

يﻮﻳر

ﻦﻣﺰﻣ

داﺪﺴﻧا

ﻪﺑ

نﺎﻳﻼﺘﺒﻣ

رد

ﻪﻴﻧﻮﻣﻮﻨﭘ

ﺎﻳﺪﻴﻣﻼﻛ

دﺎﺣ

ﺖﻧﻮﻔﻋ

عﻮﻴﺷ

ﻲﻈﻴﻔﺣ

دﻮﻌﺴﻣ

ﺮﺘﻛد

1

،

ﻲﺑﺎﺘﺳار

ﻲﻧﺎﻤﻳا

ﺎﺿر

ﺮﺘﻛد

1 *

،

يﻮﺳﻮﻣ

ﺪﻤﺤﻣ

ﺮﺘﻛد

2

ﻲﻤﻳﺮﻛ

ﻲﻠﻋ

ﺮﺘﻛد

،

3 1 ؛ناﺮﻳا ،دﺮﻛﺮﻬﺷ ،دﺮﻛﺮﻬﺷ ﻲﻜﺷﺰﭘ مﻮﻠﻋ هﺎﮕﺸﻧاد ،ﻲﻧﻮﻔﻋ يﺎﻫ يرﺎﻤﻴﺑ هوﺮﮔ 2 ﺮﻛﺮﻬﺷ ﻲﻜﺷﺰﭘ مﻮﻠﻋ هﺎﮕﺸﻧاد ،ﻲﻠﺧاد هوﺮﮔ ؛ناﺮﻳا ،دﺮﻛﺮﻬﺷ ،د 3 ناﺮﻳا ،دﺮﻛﺮﻬﺷ ،دﺮﻛﺮﻬﺷ ﻲﻜﺷﺰﭘ مﻮﻠﻋ هﺎﮕﺸﻧاد ،يژﻮﻟﻮﻨﻤﻳا و يژﻮﻟﻮﻴﺑوﺮﻜﻴﻣ هوﺮﮔ . ﺖﻓﺎﻳرد ﺦﻳرﺎﺗ : 21 / 3 / 92 ﻲﻳﺎﻬﻧ حﻼﺻا : 17 / 4 / 92 شﺮﻳﺬﭘ ﺦﻳرﺎﺗ : 29 / 4 / 92

ﻪﻣﺪﻘﻣ

:

يﻮﻳر

ﻦﻣﺰﻣ

يداﺪﺴﻧا

يرﺎﻤﻴﺑ

ﻚﺷ

نوﺪﺑ

)

Chronic Obstructive Pulmonary Disease= COPD

(

و

ﺖﺳا

نﺎﻬﺟ

ﺮﺳﺎﺗﺮﺳ

رد

ﺮﻴﻣ

و

گﺮﻣ

ﻲﻠﺻا

ﻞﻳﻻد

زا

ﻲﻜﻳ

ًﻻﺎﻤﺘﺣا

نآ

عﻮﻴﺷ

ﺪﻫاﻮﺧ

ﺶﻳاﺰﻓا

ﻪﺑ

ور

هﺪﻨﻳآ

لﺎﺳ

ﺖﺴﻴﺑ

رد

دﻮﺑ

)

3

-1

.(

ﻪﻛ

ﺎﺠﻧآ

زا

COPD

هﺪﻨﻨﻛ

ﺪﻳﺪﺸﺗ

ﻞﻣاﻮﻋ

ﺮﺛا

ﺮﺑ

مﺎﻈﻧ

ﺮﺑ

ار

ﻲﻨﻴﮕﻨﺳ

يﺎﻫ

ﻪﻨﻳﺰﻫ

،دﻮﺑ

ﺪﻫاﻮﺧ

ﺮﻳﺬﭘ

ﺖﺸﮔﺮﺑ

يرﺎﻤﻴﺑ

عﻮﻗو

دراﻮﻣ

و

ﺪﻨﻛ

ﻲﻣ

ﻞﻴﻤﺤﺗ

ﺖﻣﻼﺳ

ﻻﺎﺑ

ار

دﺮﺑ

ﻲﻣ

)

6

-4

.(

يﻮﻳر

ﻦﻣﺰﻣ

يداﺪﺴﻧا

يرﺎﻤﻴﺑ

ﺪﻳﺪﺸﺗ

AECOPD)

=

(Acute Exacerbations of Chronic Obstructive Pulmonary Disease

ﺎﻳ

ﺲﻔﻧ

ﻲﮕﻨﺗ

رد

دﺎﺣ

يﺮﻴﻴﻐﺗ

ﺎﺑ

،ﻪﻴﻟوا

ﻲﺴﻔﻨﺗ

ﻞﻜﺸﻣ

ﻴﻣ

ﺎﻳ

ﻪﻓﺮﺳ

ـــ

ناﺰ

ﻤﻫ

يروآ

ﻂﻠﺧ

ــــ

ﻪــــﺟﻮﺗ

ﻪﻛ

ﺖﺳا

هاﺮ

دﻮﺒﻬﺑ

ﺖﻳﺮﻳﺪﻣ

رد

ار

يا

هﮋﻳو

ﺪﺒﻠﻃ

ﻲﻣ

يرﺎﻤﻴﺑ

ﻦﻳا

)

7

.(

ًﺎﺒﻳﺮﻘﺗ

ﺎﻫدروآﺮﺑ

سﺎﺳا

ﺮﺑ

رد

نﻻﺎﺴﮔرﺰﺑ

ﺪﺻرد

ﺶﺷ

ﻪﺑ

ﺎﻜﻳﺮﻣآ

COPD

ﺪﻨﺘﺴﻫ

ﻼﺘﺒﻣ

)

8

(

يرﺎﻤﻴﺑ

ﺪﻳﺪﺸﺗ

و

ﻪﻌﺟاﺮﻣ

ﻪﺑ

ﺮﺠﻨﻣ

ﻪﻧﻻﺎﺳ

يﻮﻳر

ﻦﻣﺰﻣ

يداﺪﺴﻧا

13

نﻮﻴﻠﻴﻣ

دﻮﺷ

ﻲﻣ

ﻚﺷﺰﭘ

ﻪﺑ

رﺎﻤﻴﺑ

)

9

.(

و

نارﺎﻤﻴﺑ

رﺮﻜﻣ

يﺮﺘﺴﺑ

رد

ﺮﺛﻮﻣ

ﺮﻄﺧ

ﻞﻣاﻮﻋ

ﺮﺛا

ﺮﺑ

گﺮﻣ

AECOPD

ا

ﻞﻣﺎﺷ

ﺮﻛﺬﻣ

،ﻦﺳ

ﺶﻳاﺰﻓ

و

يﺮﺘﺴﺑ

ﻪﻘﺑﺎﺳ

،ندﻮﺑ

زا

نﺎﻣﺰﻤﻫ

يﺎﻫ

يرﺎﻤﻴﺑ

دﻮﺟو

ﺪﺷﺎﺑ

ﻲﻣ

ﻲﺴﻔﻨﺗ

نﻮﺧ

رﺎﺸﻓ

و

ﻢﺳآ

ﻪﻠﻤﺟ

.

ﻦﻴﻨﭽﻤﻫ

ﺎﺗ

ﻪﺘﻓﺮﮔ

ﻲﺳوﺮﻳو

عاﻮﻧا

زا

ﻲﻧﻮﻔﻋ

يﺎﻫ

نژﻮﺗﺎﭘ

دﻮﺟو

ﻤﻌﻣ

يﺎﻫ

يﺮﺘﻛﺎﺑ

عاﻮﻧا

ـــ

ﻴﻏ

و

لﻮ

ــ

ﺮــﺘﺸﻴﺑ

رد

لﻮﻤﻌﻣ

هﺪﻴﻜﭼ

:

و ﻪﻨﻴﻣز

فﺪﻫ

:

يرﺎﻤﻴﺑ يﻮﻳرﻦﻣﺰﻣيداﺪﺴﻧا ) COPD ( ﻦﻴﻣرﺎﻬﭼ،ﺖﺳاﻦﻣﺰﻣﺖﻴﺸﻧوﺮﺑومﺰﻴﻔﻣآزاﻲﺒﻴﻛﺮﺗﻪﻛ ﺪﺷﺎﺑ ﻲﻣ نﺎﻬﺟرد ﺮﻴﻣ و گﺮﻣﺖﻠﻋ . ﺪﻳﺪﺷيﻮﻳر ﻦﻣﺰﻣيداﺪﺴﻧا يرﺎﻤﻴﺑ ) AECOPD ( ﻪﺑرﻮﺒﺠﻣ ار نارﺎﻤﻴﺑ ﺖﺒﻗاﺮﻣ يﺮﻴﮕﻴﭘ ﺪﻳﺎﻤﻧ ﻲﻣ ﻲﻜﺷﺰﭘ يﺎﻫ . ،دراد ﺶﻘﻧ يرﺎﻤﻴﺑ ﻦﻳا زوﺮﺑ رد ﻪﻛ ﻲﻤﻬﻣ ﻞﻣاﻮﻋ زا ﻲﻜﻳ يﺮﺘﻛﺎﺑ ﺖﺳا ﻪﻴﻧﻮﻣﻮﻨﭘﺎﻳﺪﻴﻣﻼ . ﻪﻴﻧﻮﻣﻮﻨﭘﺎﻳﺪﻴﻣﻼﻛﺎﺑدﺎﺣﺖﻧﻮﻔﻋعﻮﻴﺷﻲﺳرﺮﺑفﺪﻫﺎﺑﻖﻴﻘﺤﺗﻦﻳا ) Chlamydia pneumoniae ( ﺖﻠﻋﻪﺑهﺪﺷشﺮﻳﺬﭘنارﺎﻤﻴﺑرد AECOPD ﺖﻓﺮﻳﺬﭘترﻮﺻدﺮﻛﺮﻬﺷﺮﺟﺎﻫنﺎﺘﺳرﺎﻤﻴﺑرد .

ﻲﺳرﺮﺑ شور

:

ﻲﻔﻴﺻﻮﺗﻪﻌﻟﺎﻄﻣﻦﻳارد -داﺪﻌﺗﻲﻌﻄﻘﻣ 100 ﻪﺑﻼﺘﺒﻣرﺎﻤﻴﺑ AECOPD ﺘﺷادﺖﻛﺮﺷ ﺪﻨ . ﺮﺑهوﻼﻋ ﻲﺘﻧآ يﺎﻫﺮﺘﻴﺗ و ﺪﺷ ﻪﺘﻓﺮﮔ نارﺎﻤﻴﺑ زا ﻪﺘﻔﻫ ﻪﺳ ﻪﻠﺻﺎﻓ ﻪﺑ ﻲﻧﻮﺧ ﻪﻧﻮﻤﻧ ود يژﻮﻟﻮﻳدار و ﻲﻨﻴﻟﺎﺑ تﺎﻨﻳﺎﻌﻣ

يدﺎﺑ

اﺰﻳﻻاشورﻪﺑﻪﻴﻧﻮﻣﻮﻨﭘﺎﻳﺪﻴﻣﻼﻛ ) ELISA ( راﺰﻓامﺮﻧزاهدﺎﻔﺘﺳاﺎﺑﺎﻫهداديرﺎﻣآﺰﻴﻟﺎﻧآوﺪﻳدﺮﮔﻦﻴﻴﻌﺗ SPSS و ﺷمﺎﺠﻧاﻲﻨﺘﻳوﻦﻣوﺮﺸﻴﻓيرﺎﻣآيﺎﻫنﻮﻣزآ .

ﺎﻫ ﻪﺘﻓﺎﻳ

:

ﻪﺑﻼﺘﺒﻣنارﺎﻤﻴﺑردﻪﻴﻧﻮﻣﻮﻨﭘﺎﻳﺪﻴﻣﻼﻛﺖﻧﻮﻔﻋعﻮﻴﺷ AECOPD

7

%

ياﻪﻄﺑارﻪﻛدﻮﺑ ﻦﻳاعﻮﻴﺷﻦﻴﺑ ﺪﺸﻧهﺪﻫﺎﺸﻣﻲﻨﻴﻟﺎﺑﻢﻳﻼﻋويرﺎﻤﻴﺑتﺪﻣلﻮﻃ،ﺖﻴﺴﻨﺟ،ﻦﺳﺎﺑيرﺎﻤﻴﺑ

)

05

/

0

> P

.(

يﺎﻫيرﺎﻤﻴﺑﻦﻴﺑلﺎﺣﻦﻳاﺎﺑ ﺎﺑهداﻮﻧﺎﺧردﻪﺑﺎﺸﻣيرﺎﻤﻴﺑويرﺎﺸﻓﺮﭘوﺖﺑﺎﻳدياﻪﻨﻴﻣز AECOPD ﻪﻄﺑار يرادﺎﻨﻌﻣ ﺪﺷهﺪﻫﺎﺸﻣ

)

05 / 0 < P

(

.

يﺮﻴﮔ ﻪﺠﻴﺘﻧ

:

ﻲﺒﺒﺳنژﻮﺗﺎﭘﻚﻳناﻮﻨﻋﻪﺑيﻮﻳرﻦﻣﺰﻣيداﺪﺴﻧايرﺎﻤﻴﺑدﺎﺣﺪﻳﺪﺸﺗردﻪﻴﻧﻮﻣﻮﻨﭘﺎﻳﺪﻴﻣﻼﻛﺶﻘﻧ ﺪﺷﺎﺑﻲﻣرادرﻮﺧﺮﺑيﺮﺘﻤﻛﺖﻴﻤﻫازاهﺪﻨﻨﻛدﺎﺠﻳاﻞﻣاﻮﻋﺮﻳﺎﺳﻪﺑﺖﺒﺴﻧ .

هژاو

يﺪﻴﻠﻛ

يﺎﻫ

:

ﻪﻴﻧﻮﻣﻮﻨﭘﺎﻳﺪﻴﻣﻼﻛ ، AECOPD ، ﺖﻧﻮﻔﻋ،اﺰﻳﻻا دﺎﺣ .

(2)

ﺖﻟﺎﺧد

يرﺎﻤﻴﺑ

ﻞﺣاﺮﻣ

ﺪﻧراد

)

10

.(

ﻠﻠﻤﻟا

ﻦﻴﺑ

يﺎﻫ

ﻞﻤﻌﻟارﻮﺘﺳد

،ﺪﻨﻛ

ﻲﻣ

ﺺﺨﺸﻣ

ﺪﻳﺪﺟ

رﺎﻤﻴﺑ

ماﺪﻛ

AECOPD

ًﻻﺎﻤﺘﺣا

ﺰﻴﻧ

ﻲﻳﺎﻳﺮﺘﻛﺎﺑ

ﺖﻧﻮﻔﻋ

رﺎﭼد

ﺖﺳا

هﺪﺷ

)

9

،

7

،

6

.(

ﻪﺑ

ﻼﺘﺑا

ﺪﺳر

ﻲﻣ

ﺮﻈﻧ

ﻪﺑ

AECOPD

ﺮﺛا

ﺮﺑ

ﻋﻮﻨﺘﻣ

ﻲﻧﻮﻔﻋ

ﺮﻴﻏ

و

ﻲﻧﻮﻔﻋ

يﺎﻫ

كﺮﺤﻣ

ﺪﻫد

ﻲﻣ

يور

.

ﺰﻧآﻮﻠﻔﻧآ

سﻮﻠﻴﻓﻮﻤﻫ

ا

)

Haemophilus Influenzae

(

،

ﻪﻴﻧﻮﻣﻮﻨﭘ

ﺲﻛﻮﻛﻮﺘﭘﺮﺘﺳا

)

Streptococcus Pneumoniae

(

و

ﺲﻴﻟارﺎﺗﺎﻛ

ﻼﺴﻛارﻮﻣ

)

Moraxella Caterrhalis

(

ﻪﺑ

زﺎﺑﺮﻳد

زا

يرﺎﻤﻴﺑ

ﻦﻳا

هﺪﻤﻋ

يﺎﻫ

نژﻮﺗﺎﭘ

ناﻮﻨﻋ

ﺪﻧا

هﺪﺷ

ﻲﻳﺎﺳﺎﻨﺷ

)

11

.(

دﺎﺣ

ﺖﻧﻮﻔﻋ

ﻲﻟﺎﻤﺘﺣا

ﺶﻘﻧ

رد

ﻪﻴﻧﻮﻣﻮﻨﭘ

ﺎﻳﺪﻴﻣﻼﻛ

ﻦﻣﺰﻣ

و

نارﺎﻤﻴﺑ

COPD

ﻪﺘﻓﺮﮔ

راﺮﻗ

ﻲﺳرﺮﺑ

درﻮﻣ

ﻲﺗﺎﻌﻟﺎﻄﻣ

رد

ﺖﺳا

)

15

-12

.(

ﻚﻳ

ﻪﻴﻧﻮﻣﻮﻨﭘ

ﺎﻳﺪﻴﻣﻼﻛ

ﺎﺑ

ﻲﻟﻮﻠﺳ

نورد

يﺮﺘﻛﺎ

ﻪﺑ

ﻪﺘﺴﺑاو

ًﻼﻣﺎﻛ

و

دﺮﻓ

ﻪﺑ

ﺮﺼﺤﻨﻣ

يزﺎﻓ

ود

ﻲﺗﺎﻴﺣ

ﻪﺧﺮﭼ

ﺖﺳا

نﺎﺑﺰﻴﻣ

ﻂﺳﻮﺗ

هﺪﺷ

ﺪﻴﻟﻮﺗ

يژﺮﻧا

.

ياراد

ﻞﻣﺎﻋ

ﻦﻳا

ﻞﺑﺎﻗ

يﺎﻫ

نﺎﻜﻴﻠﮔوﺪﻴﺘﭙﭘ

ﺪﻗﺎﻓ

ﻲﻔﻨﻣ

مﺮﮔ

ﺶﺷﻮﭘ

ﻚﻳ

ﻲﻠﭘﻮﭙﻴﻟ

نژ

ﻲﺘﻧآ

ﻚﻳ

دﻮﺧ

مﻮﻧژ

ﻂﺳﻮﺗ

و

ﺖﺳا

ﻲﻳﺎﺳﺎﻨﺷ

ﺪﻨﻛ

ﻲﻣ

ﺪﻴﻟﻮﺗ

ار

صﺎﺧ

ﺪﻳرﺎﻛﺎﺳ

)

17

،

16

.(

ﺎﻳﺪﻴﻣﻼﻛ

ﻪﻴﻧﻮﻣﻮﻨﭘ

و

ﻲﻧﺎﻗﻮﻓ

ﻲﺴﻔﻨﺗ

هﺎﮕﺘﺳد

يﺎﻫ

ﺖﻧﻮﻔﻋ

زا

ﻲﻌﻴﺳو

ﻒﻴﻃ

دﺎﺠﻳا

رد

رد

ﻪﭼ

و

ﻢﻟﺎﺳ

ﻲﻨﻤﻳا

ﻢﺘﺴﻴﺳ

ياراد

نﺎﻧﺎﺑﺰﻴﻣ

رد

ﻪﭼ

ﻲﻨﻴﻳﺎﭘ

دراد

ﺖﻛﺮﺷ

،ﻲﻨﻤﻳا

ﺺﻘﻧ

رﺎﭼد

نﺎﻧﺎﺑﺰﻴﻣ

)

18

.(

داﺮﻓا

ﻪﻤﻫ

ًﺎﺒﻳﺮﻘﺗ

ﺎﻳﺪﻴﻣﻼﻛ

ﻪﺑ

ﻲﮔﺪﻧز

لﻮﻃ

رد

رﺎﺑ

ﻚﻳ

ﻞﻗاﺪﺣ

ﺖﺳا

ﻦﻜﻤﻣ

ﺪﻧﻮﺷ

هدﻮﻟآ

ﻪﻴﻧﻮﻣﻮﻨﭘ

.

ﺮﺑ

دﺪﺠﻣ

ﺖﻧﻮﻔﻋ

بوﺎﻨﺘﻣ

يﺮﺘﻛﺎﺑ

ﻦﻳا

ﺮﺛا

دﻮﺷ

ﻞﻳﺪﺒﺗ

ﺰﻴﻧ

ﻦﻣﺰﻣ

ﺖﻧﻮﻔﻋ

ﻪﺑ

ﺖﺳا

ﻦﻜﻤﻣ

و

هدﻮﺑ

)

19

.(

ﺲﭘ

ﻲﻗﺎﺑ

نﺪﺑ

رد

ﺖﺳا

ﻦﻜﻤﻣ

ﻪﻴﻧﻮﻣﻮﻨﭘ

ﺎﻳﺪﻴﻣﻼﻛ

،ﻪﻴﻟوا

ﺖﻧﻮﻔﻋ

زا

ﺪﻧﺎﻤﺑ

)

20

(

يﺎﻫ

يرﺎﻤﻴﺑ

ياﺮﺑ

ﻲﻟﺎﻤﺘﺣا

ﺮﻄﺧ

ﻞﻣﺎﻋ

ﻚﻳ

ﻦﻳا

ﻪﻛ

ﺖﺳا

ﻦﻴﻳاﺮﺷ

ﺐﻠﺼﺗ

ﺎﻳ

ﻦﻣﺰﻣ

ﻲﺑﺎﻬﺘﻟا

يﻮﻳر

)

22

،

21

.(

ﻴﻣﻼﻛ

ﺖﻧﻮﻔﻋ

ﺺﻴﺨﺸﺗ

يﺎﻫ

شور

ﻪﻴﻧﻮﻣﻮﻨﭘ

ﺎﻳﺪ

ﺖﺳا

ﺮﻳز

دراﻮﻣ

ﻞﻣﺎﺷ

:

يﺮﺘﻛﺎﺑ

ﺖﺸﻛ

ﺖﺸﻛ

ﻂﻴﺤﻣ

رد

شور

ﻦﻳا

ﺖﻴﺳﺎﺴﺣ

ﻪﻛ

ﻲﻟﻮﻠﺳ

80

-70

ﺪﺻرد

ﺪﺷﺎﺑ

ﻲﻣ

،

ﻪﻛ

مﺮﺳ

رد

ﺎﻳﺪﻴﻣﻼﻛ

ﻪﻴﻠﻋ

ﺮﺑ

يدﺎﺑ

ﻲﺘﻧآ

رﻮﻀﺣ

ﻲﺳرﺮﺑ

نﺎﻤﻠﭙﻤﻛ

نﻮﻴﺳﺎﺴﻜﻴﻓ

ﺖﺴﺗ

مﺎﺠﻧا

نآ

ﻞﻜﺷ

ﻦﻳﺮﺗ

ﺞﻳار

)

Complement Fixationtest

(

ﺪﺷﺎﺑ

ﻲﻣ

ﻪﻛ

57

ﺪﺻرد

ﻲﻣ

شور

ﻦﻳا

ﺖﻴﺳﺎﺴﺣ

ﺪﺷﺎﺑ

،

ﻲﺳاﻮﻧﻮﻤﻳا

وﺮﻜﻴﻣ

ﺖﺴﺗ

رد

ﻲﺘﻴﺳﺎﺴﺣ

ﻪﻛ

)

Micro Immunoassay= MIF

(

دوﺪﺣ

9

/

87

ﺪﺻرد

نداد

نﺎﺸﻧ

ياﺮﺑ

و

دراد

ﻦﻴﻟﻮﺑﻮﻠﮔﻮﻨﻤﻳا

G

)

IgG

(

ﻦﻴﻟﻮﺑﻮﻠﮔﻮﻨﻤﻳا

و

M

)

IgM

(

رد

ﺎﻬﻨﺗ

ﻲﻟو

دﻮﺷ

ﻲﻣ

هدﺎﻔﺘﺳا

ﻪﻴﻧﻮﻣﻮﻨﭘ

ﺎﻳﺪﻴﻣﻼﻛ

ﺪﺿ

ﺪﺷﺎﺑ

ﻲﻣ

مﺎﺠﻧا

ﻞﺑﺎﻗ

ﺲﻧاﺮﻓر

يﺎﻫ

هﺎﮕﺸﻳﺎﻣزآ

،

شور

يﺎﻫ

ﺎﻣ

ﻲﻟﻮﻜﻟﻮﻣ

ﺪﻨﻧ

)

Polymerase Chain Reaction=PCR

(

ياراد

ﺖﻴﺳﺎﺴﺣ

87

ﺪﺻرد

ﻞﻴﻟد

ﻪﺑ

ﻲﻟو

،ﺖﺳا

ﺎﺟ

ﻪﻤﻫ

رد

ﻲﺳﺮﺘﺳد

مﺪﻋ

و

مزﻻ

يﺎﻫدراﺪﻧﺎﺘﺳا

دﻮﺒﻧ

ﺪﻨﺷﺎﺑ

ﻲﻤﻧ

ﺞﻳار

،

ﻢﻴﻘﺘﺴﻣ

يدﺎﺑ

ﻲﺘﻧآ

ﺖﻨﺳرﻮﻠﻓ

شور

)

Direct Fluorescent Antibody= DFA

(

ﻪﻛ

ﻦﻳا

شور

ﺖﻴﺳﺎﺴﺣ

ياراد

نادﺮﻣ

ياﺮﺑ

100

-70

ﺪﺻرد

اﺮﺑ

و

نﺎﻧز

ي

100

-68

ﺪﺻرد

ﺪﺷﺎﺑ

ﻲﻣ

،

ﻲﺳاﻮﻧﻮﻤﻳا

ﻢﻳﺰﻧآ

)

Enzyme Immuno Assay= EIA

(

نادﺮﻣ

ياﺮﺑ

ﻪﻛ

97

-62

ﺪﺻرد

نﺎﻧز

ياﺮﺑ

و

100

-64

ﺪﺻرد

شور

و

دراد

ﺖﻴﺳﺎﺴﺣ

اﺰﻳﻻا

)

Enzyme-Linked Immunosorbent Assay= ELISA

(

ﻪﻛ

ﺖﻴﺳﺎﺴﺣ

ياراد

ﻲﺼﻴﺨﺸﺗ

شور

ﻦﻳا

100

و

ﺪﺻرد

ﺖﻴﺻﺎﺼﺘﺧا

85

ﺪﺻرد

ﺪﺷﺎﺑ

ﻲﻣ

و

ﻪﺟﻮﺗ

ﺎﺑ

ﺮﺿﺎﺣ

لﺎﺣ

رد

ﺮﺜﻛا

رد

نآ

ﻪﺑ

نﺎﺳآ

ﻲﺳﺮﺘﺳد

و

ﻻﺎﺑ

رﺎﻴﺴﺑ

ﺖﻗد

ﻪﺑ

ﺮﻫ

دﻮﺟو

ﺎﺑ

و

دﺮﻴﮔ

ﻲﻣ

راﺮﻗ

هدﺎﻔﺘﺳا

درﻮﻣ

ﺎﻫ

هﺎﮕﺸﻳﺎﻣزآ

دﻮﻤﻧ

ﻲﺑﺎﻳزرا

ناﻮﺗ

ﻲﻣ

ار

ﻪﻧﻮﻤﻧ

يدﺎﻳز

ناﺰﻴﻣ

نآ

ﺖﻴﻛ

)

26

-23

.(

يﻻﺎﺑ

عﻮﻴﺷ

ﻪﺑ

ﻪﺟﻮﺗ

ﺎﺑ

COPD

نﺎﺘﺳا

رد

ﻤﻴﺑ

نﺪﺷ

يﺮﺘﺴﺑ

ﻪﺑ

ﺮﺠﻨﻣ

ﻪﻛ

يرﺎﻴﺘﺨﺑ

و

لﺎﺤﻣرﺎﻬﭼ

ﻪﺑ

نارﺎ

ﻪﻠﻤﺟ

زا

دﺪﻌﺘﻣ

ﻞﻳﻻد

AECOPD

بآ

ﻦﻴﻨﭽﻤﻫ

،دﻮﺷ

ﻲﻣ

رد

توﺎﻔﺗ

ﺰﻴﻧ

و

نﺎﺘﺳا

ﻦﻳا

صﺎﺧ

ﻲﻧﺎﺘﺴﻫﻮﻛ

ياﻮﻫ

و

ﻔﻋ

ياﺮﺑ

هﺪﻣآ

ﺖﺳد

ﻪﺑ

ﺮﻳدﺎﻘﻣ

ﻞﻣﺎﻋ

ﻦﻳا

ﺎﺑ

ﺖﻧﻮ

)

زا

4

ﺎﺗ

30

%

(

دﺎﺣ

ﺖﻧﻮﻔﻋ

عﻮﻴﺷ

ﻲﺳرﺮﺑ

فﺪﻫ

ﺎﺑ

ﻪﻌﻟﺎﻄﻣ

ﻦﻳا

،

رﺎﭼد

نارﺎﻤﻴﺑ

رد

ﻪﻴﻧﻮﻣﻮﻨﭘ

ﺎﻳﺪﻴﻣﻼﻛ

AECOPD

رد

ﺮﻬﺷ

ﺮﺟﺎﻫ

نﺎﺘﺳرﺎﻤﻴﺑ

ﺪﻳدﺮﮔ

اﺮﺟا

و

ﻲﺣاﺮﻃ

دﺮﻛ

.

ﻲﺳرﺮﺑ

شور

:

ﻬﺷ

ﺮﺟﺎﻫ

نﺎﺘﺳرﺎﻤﻴﺑ

ـــ

ﺟا

ﺖﻬﺟ

دﺮﻛﺮ

ﻦﻳا

ياﺮــــ

ﺪﻳدﺮﮔ

بﺎﺨﺘﻧا

ﻲﻔﻴﺻﻮﺗ

ﻲﻌﻄﻘﻣ

ﻪﻌﻟﺎﻄﻣ

.

100

رﺎﻤﻴﺑ

لﺎﺴﮔرﺰﺑ

)

53

و

دﺮﻣ

47

نز

(

ﻞﻴﻟد

ﻪﺑ

هﺪﺷ

شﺮﻳﺬﭘ

AECOPD

نﺎﺑآ

ﻪﻠﺻﺎﻓ

رد

1386

ﺖﺸﻬﺒﻳدرا

ﺎﺗ

1387

ﺪﻨﺘﻓﺮﮔ

راﺮﻗ

ﻲﺑﺎﻳزرا

درﻮﻣ

ﻪﻌﻟﺎﻄﻣ

ﻦﻳا

ياﺮﺑ

.

رﺎﻤﻴﺑ

رد

نا

(3)

ﻞﻗاﺪﺣ

ﻪﻛ

ﺪﻧﺪﺷ

ﻲﻣ

ﻪﻌﻟﺎﻄﻣ

دراو

ﻲﺗرﻮﺻ

24

ﺖﻋﺎﺳ

ﻢﺠﺣ

ﺶﻳاﺰﻓا

ﻞﻣﺎﺷ

يرﺎﻤﻴﺑ

ﺪﻳﺪﺸﺗ

زا

يراﺪﻳﺎﭘ

ﻪﻧﺎﺸﻧ

،ﺖﻣﻼﻋ

ود

ﺮﻫ

دﻮﺟو

ﺎﻳ

نآ

رد

كﺮﭼ

دﻮﺟو

،ﻂﻠﺧ

دﻮﺟو

و

ﻪﻨﻴﺳ

ﻲﮕﺘﻓﺮﮔ

،ﺲﺧ

ﺲﺧ

ﺎﻳ

ﺲﻔﻧ

ﻲﮕﻨﺗ

IgG

ﺪﻨﺷﺎﺑ

ﻪﺘﺷاد

ار

هﺪﺷ

ﺬﺧا

ﻲﻣﺮﺳ

ﻪﻧﻮﻤﻧ

رد

ﺎﻳﺪﻴﻣﻼﻛ

.

ﻪﻨﻴﺳ

زا

ﻲﻓاﺮﮔﻮﻳدار

)

ﻲﻣاﺪﻗ

يﺎﻤﻧ

-ﻲﻧوﺮﻴﺑ

يﺎﻤﻧ

و

ﻲﻔﻠﺧ

(

ﺎﻬﻧآ

ﻲﺳرﺮﺑ

زا

ﺲﭘ

و

ﺖﻓﺮﮔ

مﺎﺠﻧا

يﺮﺘﻣوﺮﻴﭙﺳا

و

يرﺎﻤﻴﺑ

ﺰﺠﺑ

ﻪﻛ

ﺪﺷ

ﺺﺨﺸﻣ

AECOPD

يﺎﻫ

يرﺎﻤﻴﺑ

،

ﺪﻧراﺪﻧ

دﻮﺟو

يﺮﮕﻳد

ﻲﺴﻔﻨﺗ

و

ﻲﺒﻠﻗ

)

رد

نارﺎﻤﻴﺑ

ﻦﻳا

رد

ﻲﻳاﻮﻫ

نﺎﻳﺮﺟ

ﺖﻳدوﺪﺤﻣ

ﻚﻳﺮﺘﻣوﺮﻴﭙﺳا

يﺎﻫﺮﺘﻣارﺎﭘ

رد

ﻲﺗرﺎﺒﻋ

ﻪﺑ

،دﻮﺒﻧ

ﺮﻳﺬﭘ

ﺖﺸﮔﺮﺑ

ًﻼﻣﺎﻛ

ﻪﻛ

ﺖﺷاد

دﻮﺟو

ﺮﺘﻣوﺮﻴﭙﺳا

ي

FEV1

زا

ﺮﺘﻤﻛ

رﻮﺗﻼﻳدﻮﻜﻧوﺮﺑ

ﺐﻗﺎﻌﺘﻣ

80

ﺪﺻرد

و

FEV1/FVC

زا

ﺮﺘﻤﻛ

70

ﺪﺻرد

رد

و

دﻮﺑ

درﻮﻣ

ﺐﻠﻗ

يﺮﻴﮔراﺮﻗ

زﺮﻃ

و

هزاﺪﻧا

ﻪﻨﻴﺳ

زا

ﻲﻓاﺮﮔﻮﻳدار

ﺖﻓﺮﮔ

راﺮﻗ

ﻲﺑﺎﻳزرا

.(

و

ﻚﻴﻓاﺮﮔﻮﻣد

تﺎﻋﻼﻃا

ﻪﻣﺎﻨﺸﺳﺮﭘ

يرﺎﻤﻴﺑ

،رﺎﻤﻴﺑ

ﻲﻠﺻا

ﺖﻳﺎﻜﺷ

،ﺲﻨﺟ

،ﻦﺳ

ﻞﻣﺎﺷ

ﻲﻜﺷﺰﭘ

رد

ﻪﺑﺎﺸﻣ

يرﺎﻤﻴﺑ

ﻪﻘﺑﺎﺳ

،يا

ﻪﻨﻴﻣز

تﺪﻣ

لﻮﻃ

،هداﻮﻧﺎﺧ

ﻪﺑ

ﻼﺘﺑا

يﺎﻫرﺎﻴﻌﻣ

و

يرﺎﻤﻴﺑ

COPD

رﺎﻤﻴﺑ

ﺮﻫ

ياﺮﺑ

ﺪﺷ

يروآدﺮﮔ

.

مﺮﺳ

يزﺎﺳاﺪﺟ

رﻮﻈﻨﻣ

ﻪﺑ

نﻮﺧ

يﺎﻫ

ﻪﻧﻮﻤﻧ

يﺮﻴﮕﻴﭘ

ﺖﻬﺟ

ﺪﻌﺑ

ﻪﺘﻔﻫ

ﻪﺳ

و

نارﺎﻤﻴﺑ

يﺮﺘﺴﺑ

ياﺪﺘﺑا

رد

ﺪﺷ

ﻪﺘﻓﺮﮔ

نارﺎﻤﻴﺑ

.

يﺎﻣد

رد

ﻲﻣﺮﺳ

يﺎﻫ

ﻪﻧﻮﻤﻧ

ﻦﻳا

20

-يﺎﻣد

رد

ﻲﺳرﺮﺑ

نﺎﻣز

ﺎﺗ

و

ﺪﻤﺠﻨﻣ

داﺮﮔ

ﻲﺘﻧﺎﺳ

ﻪﺟرد

70

-ﺪﻧﺪﺷ

يراﺪﻬﮕﻧ

داﺮﮔ

ﻲﺘﻧﺎﺳ

ﻪﺟرد

.

قﻼﺧا

ﻪﺘﻴﻤﻛ

ار

ﺶﻫوﮋﭘ

ﻦﻳا

مﺎﺠﻧا

دﺮﻛﺮﻬﺷ

ﻲﻜﺷﺰﭘ

مﻮﻠﻋ

هﺎﮕﺸﻧاد

زا

ﻪﻧﺎﻫﺎﮔآ

ﻪﻣﺎﻨﺘﻳﺎﺿر

ﻪﻌﻟﺎﻄﻣ

ياﺮﺟا

زا

ﻞﺒﻗ

و

ﺪﻴﻳﺄﺗ

ﺪﻳدﺮﮔ

ﺬﺧا

نارﺎﻤﻴﺑ

.

دﻮﺟو

Ig G

ﺖﺴﺗ

ﺎﺑ

ﻪﻴﻧﻮﻣﻮﻨﭘ

ﺎﻳﺪﻴﻣﻼﻛ

ELISA

و

ﺎﺑ

ﺎﻳﺪﻴﻣﻼﻛ

ﺺﻴﺨﺸﺗ

يﺎﻫ

ﺖﻴﻛ

زا

هدﺎﻔﺘﺳا

)

ﺖﻛﺮﺷ

ﺖﺧﺎﺳ

DRG

ﺎﻤﻟآ

ن

(

زا

هﺪﺷ

ﺖﻓﺎﻳرد

ﻲﻣﺮﺳ

يﺎﻫ

ﻪﻧﻮﻤﻧ

رد

ﺪﺷ

هداد

ﺺﻴﺨﺸﺗ

نارﺎﻤﻴﺑ

.

ﺖﻧﻮﻔﻋ

ﻚﻳژﻮﻟوﺮﺳ

تﺎﺒﺛا

ﺮﺘﻴﺗ

ﺎﺑ

دﺎﺣ

Ig G

زا

ﺮﺘﺸﻴﺑ

ﺎﻳ

ﺮﺑاﺮﺑ

512

ﺶﻳاﺰﻓا

ﺎﻳ

و

4

ﺪﻳدﺮﮔ

ﺺﺨﺸﻣ

ﺮﺘﻴﺗ

ﻦﻳا

رد

يﺮﺑاﺮﺑ

)

27

(

ﻪﻛ

ﺎﺠﻧآ

زا

و

ﺎﻳ

ﻲﻠﺒﻗ

ﺖﻧﻮﻔﻋ

ﻚﻳژﻮﻟوﺮﺳ

تﺎﺒﺛا

ياﺮﺑ

ﻲﻌﻄﻗ

رﺎﻴﻌﻣ

ﭻﻴﻫ

ﺘﻴﺗ

،ﺖﺷاﺪﻧ

دﻮﺟو

موﺎﻘﻣ

ﺖﻧﻮﻔﻋ

IgG

ﺎﺑ

ﺮﺑاﺮﺑ

64

و

زا

ﺮﺘﻤﻛ

512

و

ﻖﺑﺎﺳ

ﺖﻧﻮﻔﻋ

ﺖﻣﻼﻋ

ناﻮﻨﻋ

ﻪﺑ

ﺐﻴﺗﺮﺗ

ﻪﺑ

ﺪﺷ

ﻪﺘﻓﺮﮔ

ﺮﻈﻧ

رد

موﺎﻘﻣ

.

زا

ﺎﻫ

هداد

ﻞﻴﻠﺤﺗ

ياﺮﺑ

يرﺎﻣآ

يﺎﻫ

نﻮﻣزآ

ﺮﺸﻴﻓ

راﺰﻓا

مﺮﻧ

رد

ﻲﻨﺘﻳو

ﻦﻣ

و

SPSS

ﺪﺷ

هدﺎﻔﺘﺳا

.

ﺎﻫ

ﻪﺘﻓﺎﻳ

:

100

رﺎﻤﻴﺑ

)

53

و

دﺮﻣ

47

نز

(

ﻪﺑ

ﻼﺘﺒﻣ

AECOPD

ﻲﻨﺳ

ﻦﻴﮕﻧﺎﻴﻣ

ﺎﺑ

5

/

12

±

5

/

65

ياﺮﺑ

لﺎﺳ

يدﺎﺑ

ﻲﺘﻧآ

Ig G

راﺮﻗ

ﻲﺑﺎﻳزرا

درﻮﻣ

ﻪﻴﻧﻮﻣﻮﻨﭘ

ﺎﻳﺪﻴﻣﻼﻛ

ﺪﻨﺘﻓﺮﮔ

.

7

نارﺎﻤﻴﺑ

ﺪﺻرد

)

4

و

دﺮﻣ

3

نز

(

ﺶﻳاﺰﻓا

ياراد

ﺮﺘﻴﺗ

رد

يﺮﺑاﺮﺑ

رﺎﻬﭼ

Ig G

ﺪﻧدﻮﺑ

ﻲﻧﻮﺧ

يﺎﻫ

ﻪﻧﻮﻤﻧ

.

ﻪﺑ

ﻪﻴﻧﻮﻣﻮﻨﭘ

ﺎﻳﺪﻴﻣﻼﻛ

ﺮﻈﻧ

زا

نﺎﻧآ

ﻲﻧﻮﺧ

ﻪﻧﻮﻤﻧ

ﺮﮕﻳد

ترﺎﺒﻋ

دﻮﺑ

ﺖﺒﺜﻣ

.

ﺖﻧﻮﻔﻋ

ناﺰﻴﻣ

ﻮﻣﻮﻨﭘ

ﺎﻳﺪﻴﻣﻼﻛ

دﺎﺣ

ﻪﻄﺑار

ﻪﻴﻧ

ﻲﻨﻌﻣ

ﺖﺷاﺪﻧ

ﺲﻨﺟ

و

ﻦﺳ

ﺎﺑ

يراد

)

05

/

0

> P

.(

ﻦﻴﻨﭽﻤﻫ

ﺪﻳﺪﺸﺗ

ﺲﻔﻧ

ﻲﮕﻨﺗ

نارﺎﻤﻴﺑ

ﻲﻠﺻا

يﺎﻫ

ﻪﻳﻼﮔ

ﻪﻓﺮﺳ

و

هﺪﺷ

ﻲﻨﻌﻣ

ﻪﻄﺑار

و

دﻮﺑ

دﺎﺣ

يرﺎﻤﻴﺑ

ﻢﺋﻼﻋ

و

ﺎﻫ

ﻪﻧﺎﺸﻧ

نﺎﻴﻣ

يراد

ﻪﻴﻧﻮﻣﻮﻨﭘ

ﺎﻳﺪﻴﻣﻼﻛ

دﺎﺣ

ﺖﻧﻮﻔﻋ

ﺮﺛا

ﺮﺑ

يرﺎﻤﻴﺑ

ﺪﻳﺪﺸﺗ

و

ﺪﺸﻧ

هﺪﻫﺎﺸﻣ

)

05

/

0

> P

.(

تﺪﻣ

لﻮﻃ

ﻦﻴﮕﻧﺎﻴﻣ

COPD

ﺮﺑاﺮﺑ

5

/

2

و

لﺎﺳ

ﻦﻴﺑ

1

ﺎﺗ

10

ﻲﻨﻌﻣ

ﻪﻄﺑار

و

دﻮﺑ

لﺎﺳ

يراد

ﺪﺸﻧ

هﺪﻳد

ﻪﻴﻧﻮﻣﻮﻨﭘ

ﺎﻳﺪﻴﻣﻼﻛ

دﺎﺣ

ﺖﻧﻮﻔﻋ

ناﺰﻴﻣ

ﺎﺑ

)

05

/

0

> P

.(

ﻪﻛ

ﺪﺷ

ﺺﺨﺸﻣ

نارﺎﻤﻴﺑ

ﻪﻨﻳﺎﻌﻣ

زا

ﺲﭘ

36

ﻣز

يﺎﻫ

يرﺎﻤﻴﺑ

زا

نﺎﻧآ

ﺪﺻرد

و

ﺪﻧدﺮﺑ

ﻲﻣ

ﺞﻧر

يا

ﻪﻨﻴ

ﻲﻨﻌﻣ

ﻪﻄﺑار

ﺎﻳﺪﻴﻣﻼﻛ

دﺎﺣ

ﺖﻧﻮﻔﻋ

ناﺰﻴﻣ

نﺎﻴﻣ

يراد

ﻛا

ﻪﺑ

ﻼﺘﺑا

و

ﻪﻴﻧﻮﻣﻮﻨﭘ

ﻪﻨﻴﻣز

يﺎﻫ

يرﺎﻤﻴﺑ

ﺮﺜ

دﻮﺟو

يا

ﺖﺷاﺪﻧ

)

05

/

0

> P

(

ﻦﻴﺑ

ﺎﻬﻨﺗ

و

AECOPD

دﻮﺟو

و

و

ﺖﺑﺎﻳد

يا

ﻪﻨﻴﻣز

يرﺎﻤﻴﺑ

فﻼﺘﺧا

نﻮﺧ

يرﺎﺸﻓﺮﭘ

ﻲﻨﻌﻣ

ﺪﺷ

هﺪﻳد

يراد

)

05

/

0

< P

.(

4

و

ﺪﺻرد

73

ﺪﺻرد

ﻪﻛ

ﺪﻧدﻮﺑ

زﻮﻧﺎﻴﺳ

و

ﻲﺴﻔﻨﺗ

ﺮﺟز

رﺎﭼد

ﺐﻴﺗﺮﺗ

ﻪﺑ

نارﺎﻤﻴﺑ

زا

ﻦﻳا

زا

ماﺪﻜﭽﻴﻫ

ﻪﻄﺑار

يرﺎﻣآ

ﺮﻈﻧ

زا

ﺎﻫ

يرﺎﻤﻴ

ﻲﻨﻌ

ﺷاﺪﻧ

ﻪﻴﻧﻮﻣﻮﻨﭘ

ﺎﻳﺪﻴﻣﻼﻛ

دﺎﺣ

ﺖﻧﻮﻔﻋ

ﺎﺑ

يراد

ﺪﻨﺘ

.

ﻲﻨﻌﻣ

يرﺎﻣآ

ﻪﻄﺑار

ﭻﻴﻫ

ﻦﻴﻨﭽﻤﻫ

ﺖﻧﻮﻔﻋ

ناﺰﻴﻣ

نﺎﻴﻣ

يراد

نارﺎﻤﻴﺑ

رد

ﻪﻛ

ﻪﻴﻧﻮﻣﻮﻨﭘ

ﺎﻳﺪﻴﻣﻼﻛ

دﺎﺣ

AECOPD

يور

ﺪﺸﻧ

هﺪﻫﺎﺸﻣ

هداﻮﻧﺎﺧ

رد

ﻪﺑﺎﺸﻣ

يﺎﻫ

يرﺎﻤﻴﺑ

ﻪﻘﺑﺎﺳ

و

داد

)

05

/

0

> P

.(

نﺎﻴﻣ

ﻪﻄﺑار

ﺮﻈﻧ

زا

AECOPD

ﻪﻘﺑﺎﺳ

ﺎﺑ

ﺑﺎﺸﻣ

يﺎﻫ

يرﺎﻤﻴﺑ

ﻲﻨﻌﻣ

توﺎﻔﺗ

هداﻮﻧﺎﺧ

رد

دﻮﺑ

راد

)

05

/

0

< P

) (

لوﺪﺟ

هرﺎﻤﺷ

1

.(

(4)

هرﺎﻤﺷلوﺪﺟ 1 :

نﺎﮔﺪﻨﻨﻛ

ﺖﻛﺮﺷ

ﻲﻜﺷﺰﭘ

و

ﻚﻴﻓاﺮﮔﻮﻣد

يﺎﻫ

ﻲﮔﮋﻳو

ﺮﺘﻴﺗﺶﻳاﺰﻓايارادداﺮﻓاداﺪﻌﺗ داﺪﻌﺗ ﺎﻫﻲﮔﮋﻳو 4 53 دﺮﻣ 3 47 نز ﺲﻨﺟ 2 49 يﺮﻬﺷ 5 51 ﻲﻳﺎﺘﺳور ﺖﻣﺎﻗاﻞﺤﻣ 6 79 ﺲﻔﻧﻲﮕﻨﺗﺪﻳﺪﺸﺗ 1 18 ﻪﻓﺮﺳﺪﻳﺪﺸﺗ - 2 ﻪﻨﻴﺳﻂﻠﺧﺪﻳﺪﺸﺗ - 1 ﺐﺗ ﻼﻋوﺎﻫﻪﻧﺎﺸﻧعﻮﻧ ﺎﻫﺖﻣ - 4 دﻮﺟو 7 96 دﻮﺟومﺪﻋ درد 5 73 دﻮﺟو 2 27 دﻮﺟومﺪﻋ زﻮﻧﺎﻴﺳ 2 33 دﻮﺟو 5 67 دﻮﺟومﺪﻋ ﻪﺑﺎﺸﻣيﺎﻫيرﺎﻤﻴﺑﻲﻠﻴﻣﺎﻓﻪﻘﺑﺎﺳ 1 36 دﻮﺟو 6 64 دﻮﺟومﺪﻋ ياﻪﻨﻴﻣزيﺎﻫيرﺎﻤﻴﺑ * * ﻞﻣﺎﺷ : ﻤﻴﺑ،ﻻﺎﺑنﻮﺧرﺎﺸﻓ،ﺖﺑﺎﻳد ﺎﺳرﺎﻧ،ﻲﺒﻠﻗﻚﻴﻤﻜﺴﻳايرﺎ ﻳ يﻮﻴﻠﻛﻦﻣﺰﻣﻲﻳﺎﺳرﺎﻧوﻲﺒﻠﻗﻦﻣﺰﻣﻲ

ﺚﺤﺑ

:

ﺎﻳﺪﻴﻣﻼﻛ

دﺎﺣ

ﺖﻧﻮﻔﻋ

ﺺﻴﺨﺸﺗ

ﺮﺿﺎﺣ

ﻖﻴﻘﺤﺗ

رد

ﺶﻳاﺰﻓا

ﻲﻨﻌﻳ

ﻚﻳژﻮﻟوﺮﺳ

يﺎﻫرﺎﻴﻌﻣ

يﺎﻨﺒﻣ

ﺮﺑ

ﻪﻴﻧﻮﻣﻮﻨﭘ

ﺮﺘﻴﺗ

رد

ﺮﺑاﺮﺑ

رﺎﻬﭼ

Ig G

ﻪﻛ

داد

نﺎﺸﻧ

ﺞﻳﺎﺘﻧ

و

ﺖﺳا

هدﻮﺑ

AECOPD

رد

ﻂﻘﻓ

7

ﺪﺻرد

دﺎﺣ

ﺖﻧﻮﻔﻋ

ﺎﺑ

نارﺎﻤﻴﺑ

زا

ﺪﻴﻣﻼﻛ

ﺖﺷاد

ﻪﻄﺑار

ﻪﻴﻧﻮﻣﻮﻨﭘ

ﺎﻳ

.

ﺎﻳﺪﻴﻣﻼﻛ

ﺺﻴﺨﺸﺗ

ناﺰﻴﻣ

ﻞﻣﺎﻋ

ناﻮﻨﻋ

ﻪﺑ

دﺎﺣ

ﻪﻴﻧﻮﻣﻮﻨﭘ

AECOPD

تﺎﻌﻟﺎﻄﻣ

رد

زا

ﺮﺘﻤﻛ

زا

و

توﺎﻔﺘﻣ

نﻮﮔﺎﻧﻮﮔ

3

زا

ﺶﻴﺑ

ﺎﺗ

30

ﺪﺻرد

ﺖﺳا

هدﻮﺑ

.

يدوﺪﺣ

ﺎﺗ

ﺎﻣ

ﻪﻌﻟﺎﻄﻣ

رد

هﺪﻣآ

ﺖﺳد

ﻪﺑ

خﺮﻧ

تﺎﻘﻴﻘﺤﺗ

ﻲﺧﺮﺑ

زا

ﺮﺗﻻﺎﺑ

)

6

،

15

،

30

-28

(

رد

و

ﺪﺷﺎﺑ

ﻲﻣ

د

ﻪﺑ

ﺮﻳدﺎﻘﻣ

ﺎﺑ

ﻪﺴﻳﺎﻘﻣ

زا

ﺮﮕﻳد

ﻲﺧﺮﺑ

رد

هﺪﻣآ

ﺖﺳ

تﺎﻌﻟﺎﻄﻣ

)

29

-27

(

ﺖﺳا

ﺮﺗ

ﻦﻴﻳﺎﭘ

.

خﺮﻧ

ﻪﻌﻟﺎﻄﻣ

ﻦﻳا

رد

،نارﺎﻤﻴﺑ

رد

ﻪﻴﻧﻮﻣﻮﻨﭘ

ﺎﻳﺪﻴﻣﻼﻛ

دﺎﺣ

ﺖﻧﻮﻔﻋ

ﻪﺑ

ﻼﺘﺑا

ﻦﻴﻳﺎﭘ

ياﺮﺑ

يرﺎﺼﺤﻧا

شور

ﻚﻳ

زا

هدﺎﻔﺘﺳا

ﺖﻠﻋ

ﻪﺑ

ًﻻﺎﻤﺘﺣا

ﺖﺳا

ﻢﺴﻴﻧﺎﮔراوﺮﻜﻴﻣ

ﻦﻳا

ﻲﻳﺎﺳﺎﻨﺷ

.

ﻦﻳا

،ﺮـﮕﻳد

فﺮﻃ

زا

ﻞﻴﻟد

ﻪﺑ

ﺖﺳا

ﻦﻜﻤﻣ

توﺎﻔﺘﻣ

ﺮﻳدﺎﻘﻣ

عﻮﻧ

ندﻮﺑ

دوﺪﺤ

ﺎﻫ

ﻪﻧﻮﻤﻧ

ﺖﻓﺎﻳرد

)

،مﺮﺳ

ﻪﻧﻮﻤﻧ

ﺎﻬﻨﺗ

لﺎﺜﻣ

ناﻮﻨﻋ

ﻪﺑ

ﻲﻨﻴﺑ

يﺎﻫ

بآﻮﺳ

و

رﻻﻮﺋﻮﻟآﻮﻜﻧوﺮﺑ

ژﺎﻧرد

،يا

هﺮﺠﻨﺣ

ﻪﻨﻴﺳ

ﻂﻠﺧ

(

رﺎﻛ

ﻪﺑ

يﺎﻫ

ﺖﻴﻛ

ﺖﻴﺻﺎﺼﺘﺧا

و

ﺖﻴﺳﺎﺴﺣ

ﺰﻴﻧ

و

ﺪﺷﺎﺑ

ﻪﺘﻓر

.

ﻪﺑ

ﻼﺘﺒﻣ

نارﺎﻤﻴﺑ

يور

ﺮﺑ

ﻪﻛ

يا

ﻪﻌﻟﺎﻄﻣ

رد

ﻪﺘﺒﻟا

COPD

ﻪﻴﻧﻮﻣﻮﻨﭘ

ﺎﻳﺪﻴﻣﻼﻛ

ندﺮﻛ

اﺪﺟ

ﺪﺷ

مﺎﺠﻧا

ژﺎﻧرد

زا

رﻻﻮﺋﻮﻟآﻮﻜﻧوﺮﺑ

)

Bronchoalveolar Drainage

(

رﺎﻴﺴﺑ

ﺪﺷ

ﻲﺑﺎﻳزرا

ﻞﻜﺸﻣ

)

31

.(

ﻦﻴﺑ

يا

ﻪﻄﺑار

ﭻﻴﻫ

ﺎﻣ

ﻪﻴﻟوا

يﺎﻫ

هداد

AECOPD

ﺲﻨﺟ

و

ﻦﺳ

ﺎﺑ

ﻪﻴﻧﻮﻣﻮﻨﭘ

ﺎﻳﺪﻴﻣﻼﻛ

دﺎﺣ

ﺖﻧﻮﻔﻋ

ﻞﻴﻟد

ﻪﺑ

ﺮﮕﻳد

نﺎﻘﻘﺤﻣ

يﺎﻫ

ﻪﺘﻓﺎﻳ

ﺎﺑ

ﻪﻛ

ﺪﻧداﺪﻧ

نﺎﺸﻧ

)

33

،

32

(

ﻖﺑﺎﻄﺗ

ﺖﺷاد

.

ﺮﮕﺸﻫوﮋﭘ

زا

ﺮﮕﻳد

ﻲﺧﺮﺑ

ﻦﻴﻨﭽﻤﻫ

يا

ﻪﻄﺑار

ﭻﻴﻫ

نا

ﻦﻴﺑ

AECOPD

ﻦﺳ

و

ﻪﻴﻧﻮﻣﻮﻨﭘ

ﺎﻳﺪﻴﻣﻼﻛ

دﺎﺣ

ﺖﻧﻮﻔﻋ

ﺎﺑ

هﺪﻫﺎﺸﻣ

ﺪﻧدﺮﻜﻧ

)

12

،

37

-34

.(

(5)

و

ﻢﺋﻼﻋ

ﻦﻴﺑ

يا

ﻪﻄﺑار

ﭻﻴﻫ

ﺎﻣ

يﺎﻫ

هداد

رد

ﺎﺑ

نارﺎﻤﻴﺑ

يﺎﻫ

ﻪﻧﺎﺸﻧ

AECOPD

ﺎﻳﺪﻴﻣﻼﻛ

دﺎﺣ

ﺖﻧﻮﻔﻋ

و

ﺪﺸﻧ

هﺪﻫﺎﺸﻣ

ﻪﻴﻧﻮﻣﻮﻨﭘ

.

ﻪﻌﻟﺎﻄﻣ

رد

،ﻖﻴﻘﺤﺗ

ﻦﻳا

ﺎﺑ

ﻖﺑﺎﻄﺗ

رد

ﻳﺪﺷ

ﺲﻔﻧ

ﻲﮕﻨﺗ

ﺰﻴﻧ

يﺮﮕﻳد

ﻪﻧﺎﺸﻧ

ﻦﻳﺮﺗ

ﺞﻳار

ناﻮﻨﻋ

ﻪﺑ

AECOPD

ﻢﺋﻼﻋ

ﻦﻴﺑ

يرادﺎﻨﻌﻣ

ﻪﻄﺑار

ﭻﻴﻫ

ﻲﻟو

ﺪﺷ

ﻪﺋارا

ﺖﺷاﺪﻧ

دﻮﺟو

ﻪﻴﻧﻮﻣﻮﻨﭘ

ﺎﻳﺪﻴﻣﻼﻛ

دﺎﺣ

ﺖﻧﻮﻔﻋ

و

ﻲﻨﻴﻟﺎﺑ

)

38

.(

ﻦﻳاﺮﺑﺎﻨﺑ

AECOPD

ﺎﻳﺪﻴﻣﻼﻛ

دﺎﺣ

ﺖﻧﻮﻔﻋ

ﺖﻠﻋ

ﻪﺑ

هداد

ﺺﻴﺨﺸﺗ

ﻲﻨﻴﻟﺎﺑ

ﻢﺋﻼﻋ

يﺎﻨﺒﻣ

ﺮﺑ

ﺎﻬﻨﺗ

ﺪﻳﺎﺷ

ﻪﻴﻧﻮﻣﻮﻨﭘ

دﻮﺸﻧ

.

ﻼﺘﺑا

تﺪﻣ

لﻮﻃ

ﻦﻴﺑ

ﻦﻴﻨﭽﻤﻫ

COPD

ﺖﻧﻮﻔﻋ

و

ﻨﻌﻣ

ﻪﻄﺑار

ﭻﻴﻫ

ﻪﻴﻧﻮﻣﻮﻨﭘ

ﺎﻳﺪﻴﻣﻼﻛ

دﺎﺣ

دﻮﺟو

يراد

تﺎﻌﻟﺎﻄﻣ

ﻲﺧﺮﺑ

ﺎﺑ

ﻖﺑﺎﻄﻣ

ﻪﻛ

ﺖﺷاﺪﻧ

)

41

-39

(

ﺖﺳا

.

ﻦﻳا

ﺎﻳﺪﻴﻣﻼﻛ

دﺎﺣ

ﺖﻧﻮﻔﻋ

عﻮﻴﺷ

ﺖﻠﻋ

ﻪﺑ

ﺖﺳا

ﻦﻜﻤﻣ

ﻪﺘﻓﺎﻳ

ﺪﺷﺎﺑ

ﻞﻣﺎﻋ

ﻦﻳا

ﺎﺑ

سﺎﻤﺗ

بوﺎﻨﺗ

و

ﻪﻴﻧﻮﻣﻮﻨﭘ

.

ﺖﻧﻮﻔﻋ

ناﺰﻴﻣ

ﻦﻴﺑ

يراد

ﻲﻨﻌﻣ

ﻪﻄﺑار

ﻪﻌﻟﺎﻄﻣ

ﻦﻳا

رد

ﺎﻳﺪﻴﻣﻼﻛ

دﺎﺣ

ﺪﺸﻧ

هﺪﻫﺎﺸﻣ

يا

ﻪﻨﻴﻣز

يرﺎﻤﻴﺑ

ﺮﺜﻛا

و

ﻪﻴﻧﻮﻣﻮﻨ

.

دراﻮﻣ

لﺎﺣ

ﻦﻳا

ﺎﺑ

AECOPD

ﻲﺧﺮﺑ

ﺎﺑ

يﺮﻴﮔ

ﻢﺸﭼ

رﻮﻃ

ﻪﺑ

ﻪﺑ

يا

ﻪﻨﻴﻣز

يﺎﻫ

يرﺎﻤﻴﺑ

و

ﺪﻧدﻮﺑ

ﻂﺒﺗﺮﻣ

يا

ﻪﻨﻴﻣز

يرﺎﻤﻴﺑ

زا

ﻞﻣاﻮﻋ

ناﻮﻨﻋ

ﺎﻳﺪﻴﻣﻼﻛ

دﺎﺣ

ﺖﻧﻮﻔﻋ

ﻪﺑ

ﻼﺘﺑا

ﺮﻄﺧ

ﺶﻳاﺰﻓا

رد

ﻪﻴﻧﻮﻣﻮﻨﭘ

AECOPD

نارﺎﻤﻴﺑ

اﺮﻳز

،ﺪﻧﻮﺷ

بﻮﺴﺤﻣ

ﺖﺑﺎﻳد

ﻪﺑ

ﻼﺘﺒﻣ

ﻪﺑ

ﻼﺘﺑا

ﺮﻄﺧ

ضﺮﻌﻣ

رد

ﺮﺘﺸﻴﺑ

يرﺎﺸﻓﺮﭘ

و

ﺪﻳﺪﺸﺗ

AECOPD

ﺪﻨﺘﺷاد

راﺮﻗ

.

ﻦﻳا

ﻪﺑ

ناﻮﺗ

ﻲﻣ

ﻖﻴﻘﺤﺗ

ﻦﻳا

يﺎﻫ

ﺖﻳدوﺪﺤﻣ

زا

ﻪﻧﻮﻤﻧ

ﻢﺠﺣ

ﻪﻛ

دﺮﻛ

هرﺎﺷا

ﻪﺘﻜﻧ

ﺎﺑ

ﻖﻴﻘﺤﺗ

ياﺪﺘﺑا

رد

عﻮﻴﺷ

ضﺮﻓ

30

نﺎﻨﻴﻤﻃا

ﺎﺑ

و

ﺪﺻرد

90

يﺎﻄﺧ

و

ﺪﺻرد

ﻲﺒﺴﻧ

25

ﺪﺻرد

ﻦﻳا

يﺎﻫ

ﻪﺘﻓﺎﻳ

سﺎﺳا

ﺮﺑ

اﺬﻟ

و

ﺪﺷ

ﻦﻴﻴﻌﺗ

،ﻪﻌﻟﺎﻄﻣ

ﻮﻴﺷ

ﻪﻴﻧﻮﻣﻮﻨﭘ

ﺎﻳﺪﻴﻣﻼﻛ

دﺎﺣ

ﺖﻧﻮﻔﻋ

ع

7

ﺪﺻرد

رد

ﺪﺷ

ﻪﺘﻓﺮﮔ

ﺮﻈﻧ

.

ﻪﺠﻴﺘﻧ

يﺮﻴﮔ

:

دﺎﺣ

ﺖﻧﻮﻔﻋ

ﻪﻛ

داد

نﺎﺸﻧ

ﻪﻌﻟﺎﻄﻣ

ﻦﻳا

يﺎﻫ

ﻪﺘﻓﺎﻳ

ﻪﺑ

ﻼﺘﺒﻣ

نارﺎﻤﻴﺑ

رد

ﻪﻴﻧﻮﻣﻮﻨﭘ

ﺎﻳﺪﻴﻣﻼﻛ

AECOPD

زا

دﻮﺷ

ﻲﻤﻧ

ﻲﻘﻠﺗ

ﻢﻬﻣ

ﻲﺳﺎﻨﺷ

ﺐﺒﺳ

ظﺎﺤﻟ

.

رد

ﺎﺑ

،ﻦﻳاﺮﺑﺎﻨﺑ

رد

ﺮﮕﻳد

ﻞﻣاﻮﻋ

ﺶﻘﻧ

ﻦﺘﻓﺮﮔ

ﺮﻈﻧ

COPD

فﺪﻫ

ﺎﺑ

و

فﺎﻔﺷ

رد

ﺎﻫ

سوﺮﻳو

ﺖﻟﺎﺧد

ندﺮﻛ

AECOPD

ﻪﺑ

ﺖﺳا

زﺎﻴﻧ

يﺮﺘﺸﻴﺑ

تﺎﻌﻟﺎﻄﻣ

)

42

(

يﺎﻫدﺮﻜﻳور

ﻪﺑ

ﺎﺗ

ﻲﺘﻧآ

ﺰﻳﻮﺠﺗ

ﺶﻫﺎﻛ

ﻦﻤﺿ

و

ﻪﺘﻓﺎﻳ

ﺖﺳد

صﺎﺧ

ﻲﻧﺎﻣرد

يﺮﺘﺴﺑ

و

يروﺮﺿ

ﺮﻴﻏ

يﺎﻫ

ﻪﻨﻳﺰﻫ

ﺖﺧادﺮﭘ

زا

ﺎﻫ

ﻚﻴﺗﻮﻴﺑ

دﻮﺷ

بﺎﻨﺘﺟا

تﺪﻣ

ﻲﻧﻻﻮﻃ

يﺎﻫ

نﺪﺷ

.

ﻲﻧادرﺪﻗ

و

ﺮﻜﺸﺗ

:

ﻮﻠﻋهﺎﮕﺸﻧاديروﺎﻨﻓوتﺎﻘﻴﻘﺤﺗﺖﻧوﺎﻌﻣزا ﻲﻜﺷﺰﭘم حﺮﻃﺪﻛﺺﻴﺼﺨﺗﺖﻬﺟدﺮﻛﺮﻬﺷ 489 ﻲﻟﺎﻣيﺎﻫﺖﻳﺎﻤﺣو ﻖﻴﻘﺤﺗﻦﻳامﺎﺠﻧا ردياﻪﻧﻮﮔ ﻪﺑﻪﻛيداﺮﻓاﻪﻤﻫو حﺮﻃزا ددﺮﮔﻲﻣﺮﻜﺸﺗوﺮﻳﺪﻘﺗ،ﺪﻨﺘﺷاديرﺎﻜﻤﻫ .

ﻊﺑﺎﻨﻣ

:

1.Papaetis GS, Anastasakou E, Orphanidou D. Chlamydophila pneumoniae infection and COPD: more evidence for lack of evidence? Eur J Intern Med. 2009; 20(6): 579-85.

2.Amra B, Golshan M, Fietze I, Penzel T, Welte T. Correlation between chronic obstructive pulmonary disease and obstructive sleep apnea syndrome in a general population in Iran. J Res Med Sci. 2011; 16(7): 885-9.

3.Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006; 28(3): 523-32.

4.Lundback B, Gulsvik A, Albers M, Bakke P, Ronmark E, van den Boom G, et al. Epidemiological aspects and early detection of chronic obstructive airway diseases in the elderly. Eur Respir J Suppl. 2003; 40: 3-9.

5.Anzueto A, Sethi S, Martinez FJ. Exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2007; 4(7): 554-64.

(6)

6.Mogulkoc N, Karakurt S, Isalska B, Bayindir U, Celikel T, Korten V, et al. Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection. Am J Respir Crit Care Med. 1999; 160(1): 349-53.

7.Ghoshal AG, Dhar R, Kundu S. Treatment of acute exacerbation of COPD. J Assoc Physicians India. 2012; 60 Suppl: 38-43.

8.Mannino DM. Chronic obstructive pulmonary disease: definition and epidemiology. Respir Care. 2003; 48(12): 1185-91.

9.Martinez FJ. Pathogen-directed therapy in acute exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2007; 4(8): 647-58.

10. MacNee W. Update in chronic obstructive pulmonary disease 2007. Am J Respir Crit Care Med. 2008; 177(8): 820-9.

11. Mohan A, Premanand R, Reddy LN, Rao MH, Sharma SK, Kamity R, et al. Clinical presentation and predictors of outcome in patients with severe acute exacerbation of chronic obstructive pulmonary disease requiring admission to intensive care unit. BMC Pulm Med. 2006; 6: 27.

12. Von Hertzen LC. Chlamydia pneumoniae and its role in chronic obstructive pulmonary disease. Ann Med. 1998; 30(1): 27-37.

13. Sethi S. Bacterial infection and the pathogenesis of COPD. Chest. 2000; 117(5): 286-91. 14. Clementsen P, Permin H, Norn S. Chlamydia pneumoniae infection and its role in asthma and chronic obstructive pulmonary disease. J Investig Allergol Clin Immunol. 2002; 12(2): 73-9.

15.Papaetis GS, Anastasakou E, Tselou T, Karapanagiotou E, Botsis T, Roussou P, et al. Serological diagnosis of Chlamydophila pneumoniae infection in Greek COPD patients by microimmunofluorescence and ELISA. Med Sci Monit. 2008; 14(9): MT27-35.

16.Meijer A, Roholl PJ, Gielis-Proper SK, Meulenberg YF, Ossewaarde JM. Chlamydia pneumoniae in vitro and in vivo: a critical evaluation of in situ detection methods. J Clin Pathol. 2000; 53(12): 904-10.

17.Kumar S, Hammerschlag MR. Acute respiratory infection due to Chlamydia pneumoniae: current status of diagnostic methods. Clin Infect Dis. 2007; 44(4): 568-76.

18.Blasi F, Damato S, Cosentini R, Tarsia P, Raccanelli R, Centanni S, et al. Chlamydia pneumoniae and chronic bronchitis: association with severity and bacterial clearance following treatment. Thorax. 2002; 57(8): 672-6.

19.Grayston JT. Background and current knowledge of Chlamydia pneumoniae and atherosclerosis. J Infect Dis. 2000; 181(3): S402-10.

20.Hogan RJ, Mathews SA, Mukhopadhyay S, Summersgill JT, Timms P. Chlamydial persistence: beyond the biphasic paradigm. Infect Immun. 2004; 72(4): 1843-55.

21.Campbell LA, Kuo CC. Chlamydia pneumoniae--an infectious risk factor for atherosclerosis? Nat Rev Microbiol. 2004; 2(1): 23-32.

22.Villegas E, Sorlozano A, Gutierrez J. Serological diagnosis of Chlamydia pneumoniae infection: limitations and perspectives. J Med Microbiol. 2010; 59(Pt11): 1267-74.

23.Hajia M. A study of the efficiency of polymerase chain reaction (PCR) and fluorescent antibody test in diagnosis of Chlamydia Pneumoniae. Med J Tabriz Univ Med Sci. 2002; (55): 17-23.

24.Peeling RW. Laboratory diagnosis of Chlamydia pneumoniae infections. Can J Infect Dis. 1995; 6(4): 198-203.

25.Taylor-Robinson D, Thomas BJ. Laboratory techniques for the diagnosis of chlamydial infections. Genitourin Med. 1991; 67(3): 256-66.

(7)

26.Gutierrez J, Mendoza J, Fernandez F, Linares-Palomino J, Soto MJ, Maroto MC. ELISA test to detect Chlamydophila pneumoniae IgG. J Basic Microbiol. 2002; 42(1): 13-8.

27. Stepien E, Pieniazek P, Branicka A, Bozek M. Chlamydia pneumoniae infections-diagnostic methods. Przegl Lek. 2002; 59(3): 142-6.

28. Grayston JT, Kuo CC, Wang SP, Altman J. A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections. N Engl J Med. 1986; 315(3): 161-8.

29. Meloni F, Paschetto E, Mangiarotti P, Crepaldi M, Morosini M, Bulgheroni A, et al. Acute Chlamydia pneumoniae and Mycoplasma pneumoniae infections in community-acquired pneumonia and exacerbations of COPD or asthma: therapeutic considerations. J Chemother. 2004; 16(1): 70-6.

30. Noorbakhsh S, Javaher Tarash N, Rimaz S, Rezaei M, Tabatabaei A. Comparative study of Chlamydia pneumonia (IgM&IgG) frequency in under 14-year old children with pneumonia and in unaffected children hospitalized in pediatric ward. Razi J Med Sci. 2004; 11(43): 855-60. 31. Branden E, Gnarpe J, Hillerdal G, Orre L, Skold CM, Lofdahl M, et al. Detection of Chlamydia pneumoniae on cytospin preparations from bronchoalveolar lavage in COPD patients and in lung tissue from advanced emphysema. Int J Chron Obstruct Pulmon Dis. 2007; 2(4): 643-50.

32. Smieja M, Leigh R, Petrich A, Chong S, Kamada D, Hargreave FE, et al. Smoking, season, and detection of Chlamydia pneumoniae DNA in clinically stable COPD patients. BMC Infect Dis. 2002; 2: 12.

33. Shokouhi S, Hajikhani B, Godazgar M, Samanabadi M, Sattari M, Jamaati HR, et al. Possible effect of Chlamydophila pneumoniae on COPD exacerbation. Tanaffos. 2008; 7(1): 63-7.

34. Dowell SF, Peeling RW, Boman J, Carlone GM, Fields BS, Guarner J, et al. Standardizing hlamydia pneumoniae assays: recommendations from the centers for disease control and prevention (USA) and the laboratory centre for disease Control (Canada). Clin Infect Dis. 2001; 33(4): 492-503.

35. Seemungal TA, Wedzicha JA, MacCallum PK, Johnston SL, Lambert PA. Chlamydia pneumoniae and COPD exacerbation. Thorax. 2002; 57(12): 1087-8.

36. Dal Molin G, Longo B, Not T, Poli A, Campello C. A population based seroepidemiological survey of Chlamydia pneumoniae infections in schoolchildren. J Clin Pathol. 2005; 58(6): 617-20. 37. Kurashima K, Kanauchi T, Takayanagi N, Sato N, Tokunaga D, Ubukata M, et al. Serum IgG and IgA antibodies to Chlamydia pneumoniae and severity of emphysema. Respirology. 2005; 10(5): 572-8.

38. Murphy TF, Sethi S. Chronic obstructive pulmonary disease: role of bacteria and guide to antibacterial selection in the older patient. Drugs Aging. 2002; 19(10): 761-75.

39. Lieberman D, Lieberman D, Ben-Yaakov M, Lazarovich Z, Hoffman S, Ohana B, et al. Infectious etiologies in acute exacerbation of COPD. Diagn Microbiol Infect Dis. 2001; 40(3): 95-102.

40. Basoglu OK, Sayiner AA, Zeytinoglu A, Sayiner A. The role of atypical bacteria in acute exacerbations of chronic obstructive pulmonary disease. Turk Respir J. 2005; 6(1): 22-7.

41. Erkan L, Uzun O, Findik S, Katar D, Sanic A, Atici AG. Role of bacteria in acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008; 3(3): 463-7.

42. Wedzicha JA. Role of viruses in exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2004; 1(2): 115-20.

(8)

Cite this article as: Hafizi M, Imani-Rastabi R, Mousavi M, Karimi A. The prevalence of acute Chlamydia pneumoniae infection in patients with acute exacerbation of the chronic obstructive

pulmonary. J Shahrekord Univ Med Sci. 2013 Oct, Nov; 15(4): 93-100.

*

Corresponding author:

Infectious Diseases and Tropical Medicine Dept., Shahrekord University of Medical Sciences, Shahrekord, I.R. Iran. Tel:00989133815531, E-mail: rastabi669@gmail.com

The prevalence of acute Chlamydia pneumoniae infection in patients with

acute exacerbation of the chronic obstructive pulmonary

Hafizi M

(MD) 1

, Imani-Rastabi R

(MD)1*,

Mousavi M

(MD)2,

Karimi A

(PhD)3 1

Infectious and Tropical Diseases Dept., Shahrekord University of Medical Sciences, Shahrekord, Iran; 2Internal MedicineDept., Shahrekord University of Medical Sciences, Shahrekord, I.R. Iran; 3Microbiology and Immunology Dept., Shahrekord University of Medical

Sciences, Shahrekord, I.R. Iran.

Received: 11/June/2013 Revised: 8/July/2013 Accepted: 20/July/2013

Background and aims: The chronic obstructive pulmonary disease (COPD) is the 4th cause of morbidity in world. Acute exacerbation of COPD (AECOPD) represents a common complaint that leads patients to seek medical attention. One of the major agents that cause AECOPD is Chlamydia pneumoniae. This study was aimed to investigate the prevalence of acute C. pneumoniae infection in patients admitted with AECOPD at Hajar hospital in Shahrekord.

Methods: In this descriptive cross-sectional study, 100 patients with AECOPD were studied. In addition to clinical and radiological examinations, two blood samples were taken three weeks apart. Antibody titers against C. pneumoniae determined by enzyme- linked immunosorbent assay (ELISA).

Results: The prevalence of C. pneumoniae infection in AECOPD was 7% and no relation with age, sex, duration of disease, and clinical signs were observed (P>0.05). However, a significant relationship between diabetic diseases: having family history and high pressure and similar diseases in family with AECOPD was observed (P<0.05).

Conclusion: Our results showed Acute C. pneumoniae infection is a low significant causative pathogen in AECOPD.

References

Related documents

Strategies: EYP provided initial master planning services for the proposed 375,000 square feet of research laboratory, pilot plant, and community spaces on the 72-acre campus.

For å sammenligne med tidligere resultater foretas det også en telling av antall personer som har Leq24h 50 dBA eller høyere støynivå utenfor sin bolig for dagens situasjon og 10

Studien viser at elevane likar å ha to skuletimar ekstra trening per veke, og at dei veit om fordelane ved å vere i god fysisk form i framtidig yrke.. Dette kan gi overføringsverdi

The State Executive Committee shall be the governing body of the South Dakota FFA Association and shall consist of the State FFA Officers of the Association (President, Vice

Badawi (1973-2012) claims that the five levels of contemporary Arabic language in Egypt are: 1-“Classical Arabic”, the language of the Quran, used now in

Place branding; promotional actors; cultural intermediaries; Bourdieu; Toronto.. 20